News headlines about Arcturus Therapeutics (NASDAQ:ARCT) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arcturus Therapeutics earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.7852020877311 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Arcturus Therapeutics stock remained flat at $$7.90 during midday trading on Friday. 2,682 shares of the company’s stock were exchanged, compared to its average volume of 14,892. The firm has a market cap of $84.88 million, a price-to-earnings ratio of -2.24 and a beta of 1.18. Arcturus Therapeutics has a 52-week low of $4.78 and a 52-week high of $15.19.
ARCT has been the subject of a number of analyst reports. ValuEngine lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, April 27th. WBB Securities raised shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, June 11th. Zacks Investment Research lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, June 6th. Finally, LADENBURG THALM/SH SH raised shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Thursday, May 31st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Arcturus Therapeutics presently has a consensus rating of “Buy” and an average target price of $4.06.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.